{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:17:01Z","timestamp":1780399021494,"version":"3.54.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.bcp.2024.116335","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T15:48:08Z","timestamp":1717170488000},"page":"116335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A humanized Anti-YKL-40 antibody inhibits tumor development"],"prefix":"10.1016","volume":"225","author":[{"given":"Haihui","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziheng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2024.116335_b0005","doi-asserted-by":"crossref","first-page":"25803","DOI":"10.1016\/S0021-9258(19)74461-5","article-title":"Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family","volume":"268","author":"Hakala","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116335_b0010","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/jbmr.5650070506","article-title":"Identification of proteins secreted by human osteoblastic cells in culture","volume":"7","author":"Johansen","year":"1992","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bcp.2024.116335_b0015","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1046\/j.1432-1327.1998.2510504.x","article-title":"Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages","volume":"251","author":"Renkema","year":"1998","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bcp.2024.116335_b0020","doi-asserted-by":"crossref","first-page":"37753","DOI":"10.1074\/jbc.M303137200","article-title":"Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39","volume":"278","author":"Fusetti","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116335_b0025","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.neo.2017.11.011","article-title":"A heparin binding motif rich in arginine and lysine is the functional domain of YKL-40","volume":"20","author":"Ngernyuang","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.bcp.2024.116335_b0030","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3389\/fphys.2013.00122","article-title":"YKL-40 acts as an angiogenic factor to promote tumor angiogenesis","volume":"4","author":"Shao","year":"2013","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bcp.2024.116335_b0035","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.7150\/ijbs.67587","article-title":"The role of YKL-40 in the pathogenesis of autoimmune diseases: a comprehensive review","volume":"18","author":"Tizaoui","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bcp.2024.116335_b0040","doi-asserted-by":"crossref","first-page":"6989","DOI":"10.7150\/thno.75069","article-title":"Chitinase-3 like-protein-1 promotes glioma progression via the NF-\u03baB signaling pathway and tumor microenvironment reprogramming","volume":"12","author":"Zhao","year":"2022","journal-title":"Theranostics."},{"key":"10.1016\/j.bcp.2024.116335_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003513","article-title":"Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study","volume":"18","author":"Wallentin","year":"2021","journal-title":"PLoS Med."},{"key":"10.1016\/j.bcp.2024.116335_b0050","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-020-00303-7","article-title":"Chitinase-3 like-protein-1 function and its role in diseases","volume":"5","author":"Zhao","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2024.116335_b0055","doi-asserted-by":"crossref","first-page":"1115938","DOI":"10.3389\/fmed.2023.1115938","article-title":"YKL-40 as a possible marker of neutrophilic asthma","volume":"10","author":"Specjalski","year":"2023","journal-title":"Front Med (lausanne)."},{"key":"10.1016\/j.bcp.2024.116335_b0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12974-022-02467-1","article-title":"Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study","volume":"19","author":"Li","year":"2022","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bcp.2024.116335_b0065","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10753-021-01572-2","article-title":"Increased Plasma YKL-40 Level and Chitotriosidase Activity in Cystic Fibrosis Patients","volume":"45","author":"Topcu","year":"2022","journal-title":"Inflammation"},{"key":"10.1016\/j.bcp.2024.116335_b0070","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.12998\/wjcc.v10.i7.2184","article-title":"Prognostic value of YKL-40 in colorectal carcinoma patients: A meta-analysis","volume":"10","author":"Wang","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.bcp.2024.116335_b0075","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2217\/bmm-2023-0108","article-title":"Association of serum YKL-40 change with prognosis in acute ischemic stroke patients complicated with diabetes mellitus","volume":"17","author":"Hao","year":"2023","journal-title":"Biomark. Med."},{"key":"10.1016\/j.bcp.2024.116335_b0080","first-page":"6106","article-title":"Serum YKL-40 levels, leukocyte profiles, and acute exacerbations of advanced COPD, J","volume":"12","author":"Pope\u021biu","year":"2023","journal-title":"Clin. Med."},{"key":"10.1016\/j.bcp.2024.116335_b0085","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.3390\/cells11223568","article-title":"Upregulation of YKL-40 promotes metastatic phenotype and correlates with poor prognosis and therapy response in patients with colorectal cancer","volume":"11","author":"De Robertis","year":"2022","journal-title":"Cells."},{"key":"10.1016\/j.bcp.2024.116335_b0090","doi-asserted-by":"crossref","first-page":"1228907","DOI":"10.3389\/fimmu.2023.1228907","article-title":"Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy","volume":"14","author":"Johansen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116335_b0095","doi-asserted-by":"crossref","first-page":"15332","DOI":"10.1074\/jbc.M110.212514","article-title":"Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma","volume":"286","author":"Francescone","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116335_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216184","article-title":"YKL-40 derived from infiltrating macrophages cooperates with GDF15 to establish an immune suppressive microenvironment in gallbladder cancer","volume":"563","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2024.116335_b0105","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1186\/s12967-023-04532-6","article-title":"Cancer stem cell-derived CHI3L1 activates the MAF\/CTLA4 signaling pathway to promote immune escape in triple-negative breast cancer","volume":"21","author":"Ji","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2024.116335_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113668","article-title":"Develop companion radiopharmaceutical YKL40 antibodies as potential theranostic agents for epithelial ovarian cancer","volume":"155","author":"Chang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2024.116335_b0115","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-10-0868","article-title":"A YKL-40\u2013neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers","volume":"10","author":"Faibish","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2024.116335_b0120","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/carcin\/bgt380","article-title":"Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma","volume":"35","author":"Shao","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2024.116335_b0125","doi-asserted-by":"crossref","first-page":"12950","DOI":"10.1523\/JNEUROSCI.2017-12.2012","article-title":"Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas","volume":"32","author":"Scully","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2024.116335_b0130","doi-asserted-by":"crossref","first-page":"D301","DOI":"10.1093\/nar\/gkp946","article-title":"IMGT\/3Dstructure-DB and IMGT\/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF","volume":"38","author":"Ehrenmann","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2024.116335_b0135","first-page":"737","article-title":"IMGT\/DomainGapAlign: IMGT standardized analysis of amino acid sequences of variable, constant, and groove domains (IG, TR, MH, IgSF, MhSF)","volume":"2011","author":"Ehrenmann","year":"2011","journal-title":"Cold Spring Harb Protoc"},{"key":"10.1016\/j.bcp.2024.116335_b0140","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jmb.2007.02.100","article-title":"Analyzing the \u201cdegree of humanness\u201d of antibody sequences","volume":"369","author":"Abhinandan","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bcp.2024.116335_b0145","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0002-9440(10)64739-6","article-title":"Vasculogenic mimicry and tumor angiogenesis","volume":"156","author":"Folberg","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bcp.2024.116335_b0150","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.pathol.2017.09.015","article-title":"Chitinase 3 like 1 (CHI3L1) promotes vasculogenic mimicry formation in cervical cancer","volume":"50","author":"Ngernyuang","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.bcp.2024.116335_b0155","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.celrep.2013.07.032","article-title":"Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor \u03b12","volume":"4","author":"He","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2024.116335_b0160","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1101\/gad.210773.112","article-title":"The Hippo pathway: regulators and regulations","volume":"27","author":"Yu","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.bcp.2024.116335_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.110642","article-title":"Effect of STK3 on proliferation and apoptosis of pancreatic cancer cells via PI3K\/AKT\/mTOR pathway","volume":"106","author":"Chen","year":"2023","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bcp.2024.116335_b0170","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2024.116335_b0175","first-page":"e69","article-title":"Possible role for tocilizumab, an anti\u2013interleukin-6 receptor antibody","volume":"31","author":"Ando","year":"2013","journal-title":"Treating Cancer Cachexia, JCO."},{"key":"10.1016\/j.bcp.2024.116335_b0180","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMc1301017","volume":"368","author":"Tocilizumab for Systemic Juvenile Idiopathic Arthritis","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2024.116335_b0185","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s40425-019-0663-4","article-title":"Immunogenicity of pembrolizumab in patients with advanced tumors","volume":"7","author":"van Vugt","year":"2019","journal-title":"J. Immunotherapy Cancer."},{"key":"10.1016\/j.bcp.2024.116335_b0190","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1158\/1078-0432.CCR-19-2337","article-title":"Antidrug antibodies against immune checkpoint blockers: impairment of drug efficacy or indication of immune activation?","volume":"26","author":"Enrico","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116335_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.bcp.2024.116335_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174257","article-title":"Vascular immune evasion of mesenchymal glioblastoma is mediated by interaction and regulation of VE-Cadherin on PD-L1","volume":"15","author":"Luo","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2024.116335_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109158","article-title":"CHI3L1 predicted in malignant entities is associated with glioblastoma immune microenvironment","volume":"245","author":"Li","year":"2022","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.bcp.2024.116335_b0210","doi-asserted-by":"crossref","first-page":"e137750","DOI":"10.1172\/JCI137750","article-title":"CHI3L1 regulates PD-L1 and anti\u2013CHI3L1\u2013PD-1 antibody elicits synergistic antitumor responses","volume":"131","author":"Ma","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bcp.2024.116335_b0215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7150\/ijbs.8.39","article-title":"Two closely related human members of chitinase-like family, CHI3L1 and CHI3L2, Activate ERK1\/2 in 293 and U373 cells but have the different influence on cell proliferation","volume":"8","author":"Areshkov","year":"2011","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bcp.2024.116335_b0220","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1038\/onc.2009.292","article-title":"YKL-40, a secreted glycoprotein, promotes tumor angiogenesis","volume":"28","author":"Shao","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2024.116335_b0225","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1042\/BST20200559","article-title":"Regulation of MST complexes and activity via SARAH domain modifications","volume":"49","author":"Karchugina","year":"2021","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bcp.2024.116335_b0230","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1021\/acs.biochem.6b00763","article-title":"MST1\/MST2 protein kinases: regulation and physiologic roles","volume":"55","author":"Galan","year":"2016","journal-title":"Biochemistry"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224003186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224003186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T03:41:37Z","timestamp":1718854897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224003186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":46,"alternative-id":["S0006295224003186"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116335","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A humanized Anti-YKL-40 antibody inhibits tumor development","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116335"}}